



Product	Beyontra® (Acoramidis)
Swissmedic approval date:	18-Dec-2025
Swissmedic approval ID	70089

Bayer study ID	Study title	WS direct link
AG10-201	A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy	https://s3.amazonaws.com/ctr-bsp-7261/AG10-201/2e5dcbce-cf90-4147-a649-80f7130c6be4/8f47057b-c0a1-4d11-9b83-a39a4a0929d5/AG10-201_Study_Synopsis_CTP-v3.pdf
AG10-202	An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201	https://s3.amazonaws.com/ctr-bsp-7261/AG10-202/b316783b-1341-487d-8482-7f4ce0a2b186/4c187f3b-08f8-477e-952a-bfd397d3c8a7/AG10-202_Study_Synopsis_CTP-v3.pdf
AG10-301	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)	https://s3.amazonaws.com/ctr-bsp-7261/AG10-301/c32925a8-8bc7-4c85-813a-3e9d7322fadf/aeb15de5-d701-4ad3-ba9e-e06af80d95f3/AG10-301_Study_Synopsis_CTP-v3.pdf
ALXN2060-TAC-302	A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	https://s3.amazonaws.com/ctr-bsp-7261/ALXN2060-TAC-302/3ccdfbe9-6399-40fa-81d6-130eda87d0b0/3ce0f640-0b22-496c-92bf-390dae43ed0e/ALXN2060-TAC-302_Study_Synopsis_CTP-v3.pdf